Summary

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973. It plays a role in wound healing, tissue repair, and skin remodelling, with a substantial body of in vitro and animal evidence and a growing number of cosmetic dermatology studies. GHK-Cu is one of the most widely researched peptides in regenerative and cosmetic science.

Mechanism

GHK-Cu exerts its effects through multiple pathways. The copper(II) ion is essential for the activity of several enzymes including lysyl oxidase (cross-linking of collagen and elastin), superoxide dismutase (antioxidant defence), and tyrosinase (pigmentation). GHK-Cu modulates gene expression, upregulating genes involved in tissue repair and downregulating inflammatory and degenerative genes. It stimulates fibroblast proliferation, collagen synthesis (types I and III), and angiogenesis. The peptide also chelates copper, improving its bioavailability and cellular uptake compared to free copper ions.

Evidence base

Evidence Grading: Moderate

The evidence base for GHK-Cu is extensive in vitro and in animal models, with a smaller but growing body of human clinical data, particularly in cosmetic dermatology.

Key studies:

  • Pickart & Thaler (1973) — original isolation from human plasma
  • Pickart et al. (2015) — GHK gene expression study showing modulation of ~4,000 genes; Journal of Aging Research and Clinical Practice
  • A 2015 review in Advances in Wound Care comprehensively summarised GHK-Cu's role in skin repair and regeneration
  • Multiple in vitro studies demonstrating fibroblast stimulation and collagen synthesis

Limitations: Much of the mechanistic data is preclinical. Human clinical trials are limited and often industry-funded. No large-scale randomised controlled trials exist for systemic GHK-Cu use.

Protocols

Research protocols vary by application. In published literature:

  • Cell culture: 1–10 µM GHK-Cu
  • Topical formulations: 0.05%–3% in cream or serum bases
  • Animal studies: subcutaneous administration at research-appropriate doses

No standardised human systemic dosing protocol is established in peer-reviewed literature. All use is research-only.

GHK-Cu is not a licensed medicine in the UK and is not controlled under the Misuse of Drugs Act. It is sold as a research chemical for laboratory use. Topical GHK-Cu appears in cosmetic products regulated under UK cosmetics legislation. The MHRA does not regulate GHK-Cu as a medicinal product unless specific medicinal claims are made. Researchers should ensure compliance with UK chemicals legislation and workplace safety regulations.

Vendor notes

GHK-Cu is widely available from UK research peptide suppliers. Buyers should verify purity via certificates of analysis (COAs) and confirm third-party testing. See the vendor directory for vetted UK suppliers.

References

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature: New Biology. 1973;243(124):85–87.
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu: A Skin and Wound Repair Ingredient. Advances in Wound Care. 2015;4(9):552–563.
  3. Pickart L, Vasquez-Soltero JM, Margolina A. The Human Tripeptide GHK-Cu in Prevention of Tissue Injuries and Repair of Damaged Tissues. Journal of Aging Research & Clinical Practice. 2015;4(1):11–18.
  4. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969–988.
  5. Miller DM, DeSilva D, Fernandes L, Gulati S. The effect of copper on the immune response and the role of copper in GHK-Cu mediated wound healing. Advances in Experimental Medicine and Biology. 1990;262:233–241.